GAD2 and breast adenocarcinoma: Anti-GAD65 antibodies in patients with neurological disorders are reportedly associated with small-cell or non-small cell lung cancer, other neuroendocrine lineage neoplasms, testicular seminoma, thymoma or thymic carcinomas, thyroid neoplasia, adenocarcinomas of the breast, gastrointestinal tract, and kidney, lymphomas, and myeloma [11].